Ilya Pharma, a clinical stage immunotherapy company, has closed a €8.5 million funding round, which will be used to advance the company’s portfolio of three first-in-class immunotherapies for skin and mucosal diseases. The portfolio The active portfolio includes ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic […]